The p-MYH9/USP22/HIF-1α axis promotes lenvatinib resistance and cancer stemness in hepatocellular ca...
The p-MYH9/USP22/HIF-1α axis promotes lenvatinib resistance and cancer stemness in hepatocellular carcinoma
About this item
Full title
Author / Creator
Shan, Qiaonan , Yin, Lu , Zhan, Qifan , Yu, Jiongjie , Pan, Sheng , Zhuo, Jianyong , Zhou, Wei , Bao, Jiaqi , Zhang, Lincheng , Hong, Jiachen , Xiang, Jianan , Que, Qingyang , Chen, Kangchen , Xu, Shengjun , Wang, Jingrui , Zhu, Yangbo , He, Bin , Wu, Jingbang , Xie, Haiyang , Zheng, Shusen , Feng, Tingting , Ling, Sunbin and Xu, Xiao
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Lenvatinib is a targeted drug used for first-line treatment of hepatocellular carcinoma (HCC). A deeper insight into the resistance mechanism of HCC against lenvatinib is urgently needed. In this study, we aimed to dissect the underlying mechanism of lenvatinib resistance (LR) and provide effective treatment strategies. We established an HCC model...
Alternative Titles
Full title
The p-MYH9/USP22/HIF-1α axis promotes lenvatinib resistance and cancer stemness in hepatocellular carcinoma
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_3106862887
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3106862887
Other Identifiers
ISSN
2059-3635,2095-9907
E-ISSN
2059-3635
DOI
10.1038/s41392-024-01963-5
